לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

vetviva richter gmbh , austrija - ketamīna hidrohlorīds - šķīdums injekcijām - 100 mg/ml - aitas; cūkas; kazas; kaķi; liellopi; suņi; zirgi

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

fatro s.p.a., itālija - lincomycin hydrohloride, spectinomycin hydrochloride - šķīdums injekcijām - aitas; cūkas; kazas; liellopi

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

h. lundbeck a/s - memantine hidrohlorīds, donepezil hydrochloride - alcheimera slimība - treatment of alzheimers disease.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantine hidrohlorīds, donepezil hydrochloride - alcheimera slimība

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterīna dihidrohlorīds - fenilketonūrias - citas gremošanas trakta un metabolisma produkti, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiski līdzekļi - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedēma, iedzimta - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leikēmija, mieloīds - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - pretvemšanas un antinauseants, , serotonīns (5ht3) antagonisti - aloxi ir norādīts pieaugušajiem:novērst akūtas slikta dūša un vemšana, kas saistīta ar ļoti emetogenic vēža ķīmijterapija,profilakses, slikta dūša un vemšana, kas saistīta ar mēreni emetogenic vēža ķīmijterapija. aloxi ir norādīts pediatrijas pacientiem no 1 mēneša vecuma un vecākiem:novērst akūtas slikta dūša un vemšana, kas saistīta ar ļoti emetogenic vēža ķīmijterapija un novēršanu, slikta dūša un vemšana, kas saistīta ar mēreni emetogenic vēža ķīmijterapija.